Followers | 8 |
Posts | 744 |
Boards Moderated | 0 |
Alias Born | 07/16/2006 |
Monday, January 31, 2011 5:27:42 AM
The CC’s main theme was the introduction of SRDX’s new CEO, Gary Maharaj.
My impression is that Gary will be a pragmatist rather than a visionary. I anticipate that his primary focus will be to increase the use of SRDX’s surface modification intellectual property in medical devices marketed by other companies. In this vein, he mentioned the value of SRDX’s intellectual property with regard to enhancing the minimally invasive qualities of medical devices and reducing infections resulting from medical device use. These are the strengths of the Medical Device Division which I expect to flourish under is his leadership.
I also came away with the impression that Gary will strengthen SRDX’s research and development enterprise and de-emphasize product sales per se. This expectation raises the question: what will happen to the In Vitro Diagnostics division? .... Dan Owczarski asked essentially the same question in the Q&A. Gary responded by stating that certain segments of In Vitro are connected to SRDX’s core competency via formulation and chemistry, and in any event, In Vitro is not hurting the company, but instead providing stability during this transitional period. I took this response to mean that there won’t be any dramatic changes in the In Vitro Diagnostics franchise in the near term... It is worth noting that the growth opportunities referenced in the CC were coming from the In Vitro Diagnostics Division.
====
Selected quotes:
Recent SRDX News
- Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance • Business Wire • 05/01/2024 11:00:00 AM
- Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1 • Business Wire • 04/19/2024 11:00:00 AM
- Surmodics to Participate in Upcoming Investor Conferences in March and April • Business Wire • 02/27/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:22:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:18:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:16:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:12:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:10:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:08:12 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 04:20:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:27:42 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/02/2024 02:53:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/01/2024 01:15:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 12:00:10 PM
- Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance • Business Wire • 02/01/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/29/2024 09:29:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:46:08 PM
- Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee • Business Wire • 01/22/2024 12:30:00 PM
- Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1 • Business Wire • 01/16/2024 12:30:00 PM
- Surmodics to Host Virtual Annual Meeting of Shareholders • Business Wire • 01/16/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:45:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:26:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/18/2023 09:05:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/18/2023 09:05:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2023 09:48:08 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM